SCHEMBL30303830

SCHEMBL30303830

C=C(C)C(=O)Nc1ccc(-c2c(-c3ccc(C(=O)N4CCC5CC54)cc3)c3c(N)ncnc3n2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 4/20 0.52
▸ FGFR2 P21802 3/20 0.52
▸ FGFR3 P22607 3/20 0.52
▸ FGFR4 P22455 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ RET P07949 4/20 0.38
▸ BTK Q06187 8/20 0.35
▸ LYN P07948 2/20 0.35
▸ SRC P12931 2/20 0.35
▸ FRK P42685 2/20 0.35
▸ PTK6 Q13882 2/20 0.35
▸ LCK P06239 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ HCK P08631 1/20 0.35
▸ BLK P51451 1/20 0.35
▸ KDR P35968 2/20 0.34
▸ EGFR P00533 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22675749 1.00 FGFR1 (0.52) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22676200 0.96 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL30303405 0.96 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22677046 0.90 FGFR1 (0.49) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22676697 0.90 FGFR1 (0.49) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22677042 0.90 FGFR1 (0.49) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22676140 0.88 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22675748 0.88 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22676712 0.88 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4
SCHEMBL22677248 0.88 FGFR1 (0.51) FGFR1FGFR2FGFR3FGFR4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF D.E. SHAW RESEARCH, LLC 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR3 1/4885
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR3 1/4885
US-11780845-B2 FGFR inhibitors and methods of use thereof FGFR3, FGFR2, FGFR1 FGFR1 3/4885FGFR2 2/4885FGFR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback